Anticorps Polyclonal de lapin anti-SMARCAL1

• Phare
• Validé par KD/KO

SMARCAL1 Polyclonal Antibody for WB, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, IP, ELISA

Conjugaison

Non conjugué

Publications

2

N° de cat : 12513-1-AP

Synonymes

HARP, HepA related protein, HHARP, SMARCAL1

---

Galerie de données de validation

• 

  WB analysis of HEK-293 using 12513-1-AP

  HEK-293 cells were subjected to SDS PAGE followed by western blot with 12513-1-AP (SMARCAL1 Antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  WB analysis of Jurkat using 12513-1-AP

  Jurkat cells were subjected to SDS PAGE followed by western blot with 12513-1-AP (SMARCAL1 Antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HEK-293 using 12513-1-AP

  HEK-293 cells were subjected to SDS PAGE followed by western blot with 12513-1-AP (SMARCAL1 Antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HEK-293 using 12513-1-AP

  HEK-293 cells were subjected to SDS PAGE followed by western blot with 12513-1-AP (SMARCAL1 Antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  WB analysis of Jurkat using 12513-1-AP

  Jurkat cells were subjected to SDS PAGE followed by western blot with 12513-1-AP (SMARCAL1 antibody) at dilution of 1:300 incubated at room temperature for 1.5 hours.

• 

  WB analysis of mouse testis using 12513-1-AP

  mouse testis tissue were subjected to SDS PAGE followed by western blot with 12513-1-AP (SMARCAL1 antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

---

Applications testées

• Résultats positifs en WB: cellules HEK-293, cellules Jurkat, tissu testiculaire de souris

Dilution recommandée

• Western Blot (WB): WB : 1:500-1:1000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 1 publications below
• WB: See 2 publications below
• IP: See 1 publications below

Informations sur le produit

12513-1-AP cible SMARCAL1 dans les applications de WB, IP, ELISA et montre une réactivité avec des échantillons Humain, rat, souris

• Réactivité: Humain, rat, souris
• Réactivité citée: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: SMARCAL1 Protéine recombinante Ag3194
• Nom complet: SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a-like 1
• Masse moléculaire calculée: 954 aa, 106 kDa
• Poids moléculaire observé: 106 kDa
• Numéro d’acquisition GenBank: BC016482
• Symbole du gène: SMARCAL1
• Identification du gène (NCBI): 50485
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

SMARCAL1 is identified as a factor that favors tumor immune evasion by a dual mechanism involving both the suppression of innate immune signaling and the induction of PD-L1-mediated immune checkpoint responses. Mechanistically, SMARCAL1 limits endogenous DNA damage, thereby suppressing cGAS-STING-dependent signaling during cancer cell growth. Simultaneously, it cooperates with the AP-1 family member JUN to maintain chromatin accessibility at a PD-L1 transcriptional regulatory element, thereby promoting PD-L1 expression in cancer cells (PMID: 38301646).

Publications

Species	Application	Title
human	WB,IP	Sci Total Environ; LncRNA MT1DP promotes cadmium-induced DNA replication stress by inhibiting chromatin recruitment of SMARCAL1.; Authors - Wenya Feng
human	WB	J Exp Clin Cancer Res; RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma; Authors - Qiu Tu ; KD Validated